Nektar Therapeutics

you may press star then one on your touch-tone phone. If you're using a speaker phone, please pick up your handset before pressing the keys. To withdraw from the question queue, please press star then two. We please ask that you limit yourself to one question. If you have additional questions, you may re-enter the question queue. At this time, we will pause momentarily to assemble our roster. And the first question will come from Chris Shiv Yatani with Goldman Sachs. Please go ahead.

Yes, good afternoon. Thank you very much for the opportunity, and it's good to see progress that's being made across the programs here. If I could put my question to 358, upcoming disclosure of additional data in September. To be clear, Have we had any information about the psoriasis program? I don't believe that that had been top-lined by Lilly. Should we expect in September, in addition to the AD data, that that would be the case? And with 358, as we contemplate the different kind of immune-mediated disease indications, can you help us understand if you feel if that particular compound, this approach, 358, might be advantaged for certain patients types of indications. We've seen some early promising in lupus. There was, I believe, some disappointment in UC. If you could just help us understand how to think about that and the September readout. Thank you.

Thanks, Chris. We'll have Brian answer that question.